Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078] (ESMO Open (2021) 6(2), (S205970292100034X), (10.1016/j.esmoop.2021.100078))

G. L. Banna, A. Cortellini, D. L. Cortinovis, M. Tiseo, J. G.J.V. Aerts, F. Barbieri, R. Giusti, E. Bria, F. Grossi, P. Pizzutilo, R. Berardi, A. Morabito, C. Genova, F. Mazzoni, V. Di Noia, D. Signorelli, A. Gelibter, M. Macerelli, F. Rastelli, R. ChiariD. Rocco, S. Gori, M. De Tursi, P. Di Marino, G. Mansueto, F. Zoratto, M. Filetti, M. Montrone, F. Citarella, R. Marco, L. Cantini, O. Nigro, E. D'Argento, S. Buti, G. Minuti, L. Landi, G. Guaitoli, G. Lo Russo, A. De Toma, C. Donisi, A. Friedlaender, A. De Giglio, G. Metro, G. Porzio, C. Ficorella, A. Addeo

Research output: Contribution to journalComment/debatepeer-review

Abstract

The authors regret that the affiliations for Dr A. De Toma and Dr G. Lo Russo were incorrect when the article was published. Their correct affiliation is Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan. The authors would like to apologise for any inconvenience caused.

Original languageEnglish
Article number100137
JournalESMO Open
Volume6
Issue number3
DOIs
Publication statusPublished - Jun 2021

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078] (ESMO Open (2021) 6(2), (S205970292100034X), (10.1016/j.esmoop.2021.100078))'. Together they form a unique fingerprint.

Cite this